News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Edesa Biotech Inc
(NQ:
EDSA
)
2.570
-0.630 (-19.69%)
Streaming Delayed Price
Updated: 3:53 PM EST, Nov 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Edesa Biotech Inc
< Previous
1
2
3
Next >
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
June 24, 2024
Via
ACCESSWIRE
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
May 10, 2024
Via
ACCESSWIRE
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
April 11, 2024
Via
ACCESSWIRE
Edesa Biotech to Participate in Upcoming Investor Conferences
April 02, 2024
Via
ACCESSWIRE
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
March 21, 2024
Via
ACCESSWIRE
Edesa Biotech to Participate in Barclays Global Healthcare Conference
March 07, 2024
Via
ACCESSWIRE
Edesa Biotech to Participate in Upcoming Dermatology Meetings
March 04, 2024
Via
ACCESSWIRE
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
February 09, 2024
Via
ACCESSWIRE
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
January 04, 2024
Via
ACCESSWIRE
Edesa Biotech Reports Fiscal Year 2023 Results
December 15, 2023
Via
ACCESSWIRE
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
November 20, 2023
Via
ACCESSWIRE
Edesa Biotech to Present at Dermatology Drug Development Summit
October 26, 2023
Via
ACCESSWIRE
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug
October 25, 2023
Via
ACCESSWIRE
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
October 12, 2023
Via
ACCESSWIRE
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
October 12, 2023
Via
ACCESSWIRE
Edesa Biotech Announces One-for-Seven Reverse Share Split
October 10, 2023
Via
ACCESSWIRE
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
September 28, 2023
Via
ACCESSWIRE
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
August 09, 2023
Via
ACCESSWIRE
Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
July 26, 2023
Via
ACCESSWIRE
Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
June 28, 2023
Via
ACCESSWIRE
Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
June 27, 2023
Via
ACCESSWIRE
Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
May 11, 2023
Via
ACCESSWIRE
Edesa Biotech to Participate in Swiss Biotech Day
April 20, 2023
Via
ACCESSWIRE
The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
April 04, 2023
Via
ACCESSWIRE
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
March 23, 2023
Via
ACCESSWIRE
Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
March 16, 2023
Via
ACCESSWIRE
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
March 15, 2023
Via
ACCESSWIRE
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
February 10, 2023
Via
ACCESSWIRE
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
February 01, 2023
Via
ACCESSWIRE
Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
January 17, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
